Conservative or Operative Therapy in Patients With a Fragility Fracture of the Pelvis
Launched by BJÖRN-CHRISTIAN LINK · Feb 5, 2021
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best treatment options for older patients who have a fragility fracture of the pelvis, which usually happens from a small fall or minor injury. Specifically, the trial is looking at two treatment methods: a less invasive surgery to stabilize the pelvis and a non-surgical approach that involves managing pain and allowing the body to heal naturally. Researchers want to find out which of these treatments works better in helping patients recover and improve their quality of life over a year.
To be eligible for the trial, participants must be adults who have a specific type of pelvic fracture (FFP IIb or IIc) caused by a low-energy fall, and they should have been able to walk at least 4 meters before the injury. Throughout the trial, which will last about 18 months, participants will be randomly assigned to one of the two treatment groups. They will be followed up at 4 weeks, 4 months, and 1 year to assess their recovery, including their pain levels and ability to move. This research aims to help determine the best approach for treating this type of fracture, ultimately improving care for elderly patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent as documented by signature
- • The fracture must be a fragility fracture. This means absence of high energy trauma.
- • Fragility fracture of the sacrum (FFP II b + c). Involvement of the ventral pelvic ring is not an exclusion criteria.
- • Able to walk 4 meters before fracture
- Exclusion Criteria:
- • Patients who had a high energy trauma.
- • FFP I or FFP III+IV were operative therapy is recommended
- • Patient who are not operable according to the anaesthesiologist on call.
- • Open fractures.
- • Revision surgeries.
- • Absent contact information
- • Living abroad and cannot participate in follow-up visits.
- • Withdrawal from the study.
About Björn Christian Link
Björn-Christian Link is a dedicated clinical trial sponsor renowned for its commitment to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, the organization collaborates with leading researchers and institutions to conduct rigorous clinical trials across various therapeutic areas. Björn-Christian Link prioritizes patient safety and ethical standards, ensuring that all studies are conducted with the utmost integrity and transparency. By leveraging cutting-edge methodologies and a patient-centered approach, the sponsor aims to contribute significantly to the scientific community and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lucerne, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials